Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS Wildtype”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06682572
What this trial is testing

Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients

Who this might be right for
Low Grade Serous Ovarian CancerOvarian Cancer
Verastem, Inc. 16
Testing effectiveness (Phase 2)UnknownNCT01384994
What this trial is testing

Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients

Who this might be right for
Colorectal CancerKRAS WildtypeAfter Resection of Liver Metastases
PD Dr. med. Volker Heinemann 111
Testing effectiveness (Phase 2)Active Not RecruitingNCT04117945
What this trial is testing

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

Who this might be right for
BRAF V600E NegativeKRAS Gene Mutation NegativeLocally Advanced Unresectable Colorectal Adenocarcinoma+10 more
Academic and Community Cancer Research United 22
Not applicableStudy completedNCT03914170
What this trial is testing

Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Institut du Cancer de Montpellier - Val d'Aurelle 70
Testing effectiveness (Phase 2)Ended earlyNCT01718808
What this trial is testing

Cetuximab for Elderly Patients With mCRC

Who this might be right for
Metastatic Colorectal Cancer
Swiss Cancer Institute 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT04625270
What this trial is testing

Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Who this might be right for
Low Grade Ovarian Serous AdenocarcinomaOvarian Cancer
Verastem, Inc. 225
Testing effectiveness (Phase 2)Study completedNCT00553254
What this trial is testing

Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

Who this might be right for
Carcinoma, Non Small Cell Lung
Pfizer 55
Testing effectiveness (Phase 2)Study completedNCT05775900
What this trial is testing

Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Sun Yat-sen University 24
Testing effectiveness (Phase 2)Study completedNCT01226719
What this trial is testing

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Who this might be right for
Colorectal Cancer
SCRI Development Innovations, LLC 15
Testing effectiveness (Phase 2)Ended earlyNCT01351038
What this trial is testing

Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

Who this might be right for
KRAS Wild TypeResectable Type II Gastric Adenocarcinoma
Arbeitsgemeinschaft medikamentoese Tumortherapie 43
Large-scale testing (Phase 3)Ended earlyNCT01309126
What this trial is testing

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Who this might be right for
Colorectal Cancer
HiberCell, Inc. 217
Early research (Phase 1)Study completedNCT06056024
What this trial is testing

Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

Who this might be right for
Solid Tumor, KRAS Mutation
Boehringer Ingelheim 47
Testing effectiveness (Phase 2)Study completedNCT01358812
What this trial is testing

FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colo-rectal Cancer
Gruppo Oncologico del Nord-Ovest 37
Testing effectiveness (Phase 2)Study completedNCT02337530
What this trial is testing

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Canadian Cancer Trials Group 62
Early research (Phase 1)Study completedNCT01787500
What this trial is testing

Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

Who this might be right for
BRAF NP_004324.2:p.V600XKRAS wt AlleleMetastatic Malignant Solid Neoplasm+4 more
M.D. Anderson Cancer Center 47
Testing effectiveness (Phase 2)Study completedNCT02337946
What this trial is testing

Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma

Who this might be right for
Colorectal Carcinoma
Takeda 164
Large-scale testing (Phase 3)Study completedNCT01229813
What this trial is testing

Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.

Who this might be right for
Colorectal Cancer
Lund University Hospital 233
Testing effectiveness (Phase 2)Study completedNCT01276379
What this trial is testing

Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab

Who this might be right for
Colorectal Cancer
Grupo Espanol Multidisciplinario del Cancer Digestivo 221
Testing effectiveness (Phase 2)Study completedNCT00788957
What this trial is testing

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

Who this might be right for
Colon CancerColorectal CancerGastrointestinal Cancer+2 more
NantBioScience, Inc. 177
Testing effectiveness (Phase 2)Study completedNCT03446157
What this trial is testing

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

Who this might be right for
Cancer of the ColonColon CancerColon Neoplasms+2 more
UNC Lineberger Comprehensive Cancer Center 24
Next Page